Activity
Sanofi gains AATD hopeful with $1.7-billion deal for Inhibrx
sanofi, Inhibrx, Acquisition (action), alpha 1-Antitrypsin Deficiency, Market
Bristol Myers’ Opdivo fails part two of post-kidney cancer surgery test as competitor Merck touts new survival data
Bristol, Myers, Opdivo, post-kidney cancer surgery test, Continuance of life
Talc marketing claims against J&J close to potential settlement with 40+ states
Settlement and Resettlement, Johnson and Johnson, J&J’s